Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have signed a consent form agreeing to take part in the study
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body (specifically a type called pancreatic ductal adenocarcinoma)
- You have been experiencing significant unintentional weight loss related to your cancer (a condition called cachexia, confirmed using specific medical guidelines)
- You have completed either one full round (28 days) of a chemotherapy combination called nab-paclitaxel and gemcitabine, or two rounds of a chemotherapy called FOLFIRINOX, and are due to start your next round of chemotherapy
- You are in generally good physical condition (able to carry out light activity) and your doctors expect you to live for at least 4 months
Who may not be able to join:
- You have another identifiable and treatable reason for eating less than normal
- Your weight loss is being caused by something other than your cancer
- You have ever been diagnosed with heart failure, regardless of how mild or severe it was
- A heart scan shows that your heart is pumping at less than 50% of its normal capacity
- You are currently receiving nutrition through a feeding tube or directly into a vein
- You have previously had a serious allergic reaction to any antibody-based treatment or diagnostic agent
- You have a known allergy or sensitivity to any of the chemotherapy drugs used in this trial or their ingredients
- You have a different type of pancreatic cancer (such as neuroendocrine or acinar), or you have cancer that has spread to the brain or the lining around the brain
- Your liver is not functioning well enough (confirm with trial site for specific levels)
- Your kidneys are not working well enough, or you require dialysis (confirm with trial site for specific levels)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent change from baseline in body weight for ponsegromab compared to placebo; Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.